Health Economics, The University of Sydney, NHMRC Clinical Trials Centre, Sydney, New South Wales, Australia.
Wolfson Palliative Care Research Centre, Hull York Medical School, University of Hull, Hull, UK.
BMJ Open. 2019 May 19;9(5):e027776. doi: 10.1136/bmjopen-2018-027776.
To measure health-related quality of life (HRQoL) and well-being in older people with end-stage kidney disease (ESKD) and to determine the association between treatment type and sociodemographic characteristics on these outcome measures. In addition, to assess the convergent validity between the HRQoL and well-being measure and their feasibility and acceptability in this population.
Prospective cross-sectional study.
Three renal units in the UK and Australia.
129 patients with ESKD managed with dialysis or with an estimated glomerular filtration ≤10 mL/min/1.73 m and managed with comprehensive conservative, non-dialytic care.
HRQoL and well-being were assessed using Short-Form six dimensions (SF-6D, 0-1 scale); Kidney Disease Quality of Life (KDQOL-36) (0-100 scale) and Investigating Choice Experiments Capability Measure-Older people (ICECAP-O, 0-1 scale). Linear regression assessed associations between treatment, HRQoL and well-being. Pearson's correlation coefficient assessed convergent validity between instruments.
Median age of 81 years (IQR 78-85), 65% males; 83 (64%) were managed with dialysis and 46 (36%) with conservative care. When adjusted for treatment type and sociodemographic variables, those managed on dialysis reported lower mean SF-6D utility (-0.05, 95% CI -0.12 to 0.01); lower KDQOL Physical Component Summary score (-3.17, 95% CI -7.61 to 1.27); lower Mental Component Summary score (-2.41, 95% CI -7.66 to 2.84); lower quality of life due to burden (-28.59, 95% CI -41.77 to -15.42); symptoms (-5.93, 95% CI -14.61 to 2.73) and effects of kidney disease (-16.49, 95% CI -25.98 to -6.99) and lower overall ICECAP-O well-being (-0.07, 95% CI -0.16 to 0.02) than those managed conservatively. Correlation between ICECAP-O well-being and SF-6D utility scores was strong overall, 0.65 (p<0.001), but weak to moderate at domain level.
Older people on dialysis report significantly higher burden and effects of kidney disease than those on conservative care. Lower HRQoL and well-being may be associated with dialysis treatment and should inform shared decision-making about treatment options.
UK (IRAS project ID: 134360andREC reference 14/LO/0291) and Australia (R20140203 HREC/14/RAH/36).
测量终末期肾病(ESKD)老年人的健康相关生活质量(HRQoL)和幸福感,并确定治疗类型与社会人口统计学特征对这些结果的相关性。此外,评估 HRQoL 和幸福感测量之间的趋同效度以及在该人群中的可行性和可接受性。
前瞻性横断面研究。
英国和澳大利亚的三个肾脏单位。
129 名 ESKD 患者,接受透析治疗或估计肾小球滤过率≤10ml/min/1.73m,接受全面保守、非透析治疗。
采用简短六维健康状况量表(SF-6D,0-1 量表)、肾脏病生活质量量表(KDQOL-36,0-100 量表)和调查选择实验能力量表-老年人(ICECAP-O,0-1 量表)评估 HRQoL 和幸福感。线性回归评估治疗、HRQoL 和幸福感之间的相关性。Pearson 相关系数评估工具之间的趋同效度。
中位年龄 81 岁(IQR 78-85),65%为男性;83 例(64%)接受透析治疗,46 例(36%)接受保守治疗。调整治疗类型和社会人口统计学变量后,接受透析治疗的患者 SF-6D 效用评分较低(-0.05,95%CI -0.12 至 0.01);KDQOL 身体成分综合评分较低(-3.17,95%CI -7.61 至 1.27);心理成分综合评分较低(-2.41,95%CI -7.66 至 2.84);由于负担导致的生活质量较低(-28.59,95%CI -41.77 至 -15.42);症状(-5.93,95%CI -14.61 至 2.73)和肾脏疾病的影响(-16.49,95%CI -25.98 至 -6.99);整体 ICECAP-O 幸福感较低(-0.07,95%CI -0.16 至 0.02)。与保守治疗相比,接受透析治疗的患者报告的负担和肾脏疾病的影响明显更高。较低的 HRQoL 和幸福感可能与透析治疗有关,并应告知关于治疗选择的共同决策。
英国(IRAS 项目 ID:134360 和 REC 参考 14/LO/0291)和澳大利亚(R20140203 HREC/14/RAH/36)。